Acetylsalicyclic acid (Fast acting Aspirin, BAY1019036) + Acetylsalicyclic acid (Aspirin, BAYE4465) + Placebo
Phase 3Completed 0 watching 0 views this week📈 Rising
74
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Drugs, Investigational
Conditions
Drugs, Investigational
Trial Timeline
Apr 29, 2010 → Aug 6, 2010
NCT ID
NCT01122602About Acetylsalicyclic acid (Fast acting Aspirin, BAY1019036) + Acetylsalicyclic acid (Aspirin, BAYE4465) + Placebo
Acetylsalicyclic acid (Fast acting Aspirin, BAY1019036) + Acetylsalicyclic acid (Aspirin, BAYE4465) + Placebo is a phase 3 stage product being developed by Bayer for Drugs, Investigational. The current trial status is completed. This product is registered under clinical trial identifier NCT01122602. Target conditions include Drugs, Investigational.
Hype Score Breakdown
Clinical
27
Activity
18
Company
7
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01122602 | Phase 3 | Completed |
Competing Products
6 competing products in Drugs, Investigational
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| HR17031 injection + insulin glargine | Jiangsu Hengrui Medicine | Phase 3 | 77 |
| SHR-1603 | Jiangsu Hengrui Medicine | Phase 1 | 33 |
| Famitinib + Ifosfamide + Camrelizumab | Jiangsu Hengrui Medicine | Phase 1/2 | 41 |
| bictegravir/emtricitabine/tenofovir alafenamide (BIC/F/TAF) | Gilead Sciences | Pre-clinical | 22 |
| Sintilimab | Innovent Biologics | Phase 2 | 51 |
| Acetylsalicylic acid (Fast release Aspirin, BAY1019036) + Acetylsalicylic Acid (Aspirin, BAYE4465) + Placebo | Bayer | Phase 3 | 74 |